Gossamer Bio's Q3 net loss widens to $48.2 mln

Gossamer Bio

05/11/2025 21:23

Overview

Gossamer Bio Q3 revenue from collaborations rises to $13.3 mln, up from $9.5 mln in 2024

Net loss for Q3 widens to $48.2 mln from $30.8 mln in 2024

Outlook

Company expects topline results from PROSERA Phase 3 Study in February 2026

First site activated for SERANATA Phase 3 Study in PH-ILD

Company's cash reserves expected to fund operations into 2027

Result Drivers

R&D EXPENSES - Increase in R&D expenses to $45.5 mln from $34.9 mln in 2024 due to ongoing clinical trials

COLLABORATION REVENUE - Revenue from collaboration with Chiesi increased to $13.3 mln from $9.5 mln in 2024

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
-$0.21
Q3 Net Income
-$48.22 mln
Q3 Basic EPS
-$0.21
Q3 Operating Expenses
$62.41 mln
Q3 Operating Income
-$49.11 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Gossamer Bio Inc is $9.00, about 74.4% above its November 4 closing price of $2.30

Press Release: ID:nBw46f6tta

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)